Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited (RGC) Financial Performance & Income Statement Overview
Review Regencell Bioscience Holdings Limited (RGC) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Regencell Bioscience Holdings Limited (RGC) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Regencell Bioscience Holdings Limited RGC financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $581483.00 | $291.00 | $242.00 | $242.00 |
| SG&A Expenses | $1.84M | $978.00 | $914.00 | $914.00 |
| Operating Expenses | $2.42M | $1212.00 | $1156.00 | $1156.00 |
| Total Costs & Expenses | $2.42M | $1212.00 | $1156.00 | $1156.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $247540.00 | $73.00 | $73.00 | $73.00 |
| EBITDA | -$2.18M | -$1139.00 | -$2.19M | -$1.08M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$2.42M | -$1212.00 | -$1156.00 | -$1156.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $247543.00 | $124.00 | -$1.03M | -$1.09M |
| Income Before Tax | -$2.18M | -$1089.00 | -$1093.00 | -$1093.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $57887.00 | $0.00 | -$119271.00 | -$60.00 |
| Net Income | -$2.24M | -$1118.00 | -$1033.00 | -$1033.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.004 | -$0.00 | -$0.00 | -$0.00 |
| Diluted EPS | -$0.004 | -$0.00 | -$0.00 | -$0.00 |
| Weighted Avg Shares Outstanding | $494.49M | $494.49M | $494.49M | $494.49M |
| Weighted Avg Shares Outstanding (Diluted) | $494.49M | $494.47M | $494.46M | $494.46M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q1 2024 to $0.00 in Q4 2024. Gross profit remained healthy with margins at N/A in Q4 2024 compared to N/A in Q1 2024. Operating income hit -$2.42M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.18M. Net income dropped to -$2.24M, while earnings per share reached -$0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan